Short answer
Dexcom (DXCM) filed its Q1 2026 10-Q quarterly report on Apr 30, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $1.2B (up 15.0% year over year) with net income of $200M.
Q1 2026 key financials · XBRL
- Revenue
- $1.2B
- +15.0% YoY
- Net income
- $200M
- +89.3% YoY
- Operating margin
- 21.4%
- Gross margin
- 62.9%
- EPS (diluted)
- $0.51
- +88.9% YoY
Source: XBRL data from the Dexcom (DXCM) Q1 2026 10-Q on SEC EDGAR. USD.
Dexcom Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- No profitability or margin percentages provided
- Forward-looking statements subject to risks and uncertainties; no updated guidance disclosed
Risk Factors
- No material changes to previously disclosed risks in the December 31, 2025 Form 10-K
- Broad unidentified risks potentially materially adverse to business, financial condition, results, or prospects
- Stock-price risk, including potential loss of all or part of stockholders’ investment
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Dexcom quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.